Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Erika L. Crowley, Novin Nezamololama, Kim Papp & Melinda J. Gooderham. (2020) Abrocitinib for the treatment of atopic dermatitis. Expert Review of Clinical Immunology 16:10, pages 955-962.
Read now
Read now
A. Bilgic & D. F. Murrell. (2019) What is novel in the clinical management of pemphigus. Expert Review of Clinical Pharmacology 12:10, pages 973-980.
Read now
Read now
Articles from other publishers (29)
Tianqi Liu, Ruonan Gao, Li Li, Bin Wu & Fengbo Wu. (2023) Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System. International Journal of Clinical Pharmacy 45:6, pages 1483-1491.
Crossref
Crossref
Johan Mattsson, Elisabeth Israelsson, Karin Björhall, Linda Fahlén Yrlid, Kristoffer Thörn, Anna Thorén, Emelie Andersén Toledo, Lisa Jinton, Lisa Öberg, Cecilia Wingren, Sofia Tapani, Sonya G. Jackson, Gabriel Skogberg, Anders J. Lundqvist, Ramon Hendrickx, Anders Cavallin, Torben Österlund, Neil P. Grimster, Magnus Nilsson & Annika Åstrand. (2023) Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata. Skin Health and Disease 3:3.
Crossref
Crossref
Won Tae Jo, A Young Kim, Hyun Goo Woo, Hae Jun Song & Eun Joo Baik. (2023) Effect of Janus Kinase 3 Inhibitor on Sebaceous Gland Regeneration during Skin Wound Healing. Annals of Dermatology 35:4, pages 275.
Crossref
Crossref
Mario F. Muñoz, Sandro Argüelles, Antonio Ayala & Francesco Marotta. 2023. Anti-Aging Pharmacology. Anti-Aging Pharmacology
285
304
.
Yue Xiao, Hongmei Xiang & Wei Li. (2022) Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib. Dermatologic Therapy 35:10.
Crossref
Crossref
Samantha Sarabia, Brandan Ranjith, Sahil Koppikar & Don Thiwanka Wijeratne. (2022) Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis. BMC Rheumatology 6:1.
Crossref
Crossref
Jiali Zhuang, Arkaitz Ibarra, Alexander Acosta, Amy P. Karns, Jonathan Aballi, Michael Nerenberg, John J. Sninsky, Stephen R. Quake & Shusuke Toden. (2022) Survey of extracellular communication of systemic and organ-specific inflammatory responses through cell free messenger RNA profiling in mice. eBioMedicine 83, pages 104242.
Crossref
Crossref
Ishan Agarwal, Maitreyee Panda & Anupam Das. (2022) Tofacitinib in paediatric dermatoses: a narrative review. Clinical and Experimental Dermatology 47:7, pages 1256-1264.
Crossref
Crossref
Eva Štěpánková, Pavla Boháčová & Monika Arenbergerová. (2022) Alopecia areata - basic disease characteristics and an overview of current and new treatment options. Dermatologie pro praxi 16:1, pages 9-12.
Crossref
Crossref
Suchitra Nishal, Vikas Jhawat, Parmita Phaugat & Rohit Dutt. (2022) Rheumatoid Arthritis and JAK-STAT Inhibitors: Prospects of Topical Delivery. Current Drug Therapy 17:2, pages 86-95.
Crossref
Crossref
Jie Dong, Xuan Huang, Li-Ping MaFei Qi, Si-Nian Wang, Zi-Qin Zhang, Shi-Nan Wei, Ling Gao & Fang Liu. (2022) Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro. Dose-Response 20:2, pages 155932582211053.
Crossref
Crossref
Charlotte S. Greif, Divya Srivastava & Rajiv I. Nijhawan. (2021) Janus Kinase Inhibitors and Non-Melanoma Skin Cancer. Current Treatment Options in Oncology 22:2.
Crossref
Crossref
May El Hachem, Giuseppe Di Mauro, Roberta Rotunno, Simona Giancristoforo, Cristiana De Ranieri, Carla Maria Carlevaris, Maria Carmen Verga & Iride Dello Iacono. (2020) Pruritus in pediatric patients with atopic dermatitis: a multidisciplinary approach - summary document from an Italian expert group. Italian Journal of Pediatrics 46:1.
Crossref
Crossref
C. Erfurt‐Berge & M. Sticherling. (2020) Successful treatment of ulcerative necrobiosis lipoidica with janus kinase inhibitor. Journal of the European Academy of Dermatology and Venereology 34:7.
Crossref
Crossref
E. Guang-Xin, Bai-Gao Yang, Yan-Bin Zhu, Xing-Hai Duang, Wang-Dui Basang, Xiao-Lin Luo & Tian-Wu An. (2020) Genome-wide selective sweep analysis of the high-altitude adaptability of yaks by using the copy number variant. 3 Biotech 10:6.
Crossref
Crossref
Ying-Xiu Dai, Chen-Pu Yeh & Chih-Chiang Chen. (2020) Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata. Dermatologica Sinica 38:1, pages 3.
Crossref
Crossref
Jessica Carolina Martinez-Rico, Jesus Ancer-Arellano, Adrian Martinez-Moreno, Sonia Sofia Ocampo-Garza, Jorge Ocampo-Candiani & Sonia Chavez-Alvarez. (2020) Frontal Fibrosing Alopecia and Autoimmune Disorders in a Hispanic Female. Skin Appendage Disorders 6:6, pages 362-365.
Crossref
Crossref
Ana M. Montilla, Francisco Gómez-García, Pedro J. Gómez-Arias, Jesús Gay-Mimbrera, Jorge Hernández-Parada, Beatriz Isla-Tejera & Juan Ruano. (2019) Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata. Dermatology and Therapy 9:4, pages 655-683.
Crossref
Crossref
Soheil Tavakolpour, HamidReza Mahmoudi, Robabeh Abedini, Kambiz. Kamyab Hesari, Amin Kiani & Maryam Daneshpazhooh. (2019) Frontal fibrosing alopecia: An update on the hypothesis of pathogenesis and treatment. International Journal of Women's Dermatology 5:2, pages 116-123.
Crossref
Crossref
Nicole Relke & Melinda Gooderham. (2019) The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature. Journal of Cutaneous Medicine and Surgery 23:3, pages 298-306.
Crossref
Crossref
Francisco Gómez-García, Pedro Jesús Gómez-Arias, Jorge Hernandez, Ana María Montilla, Jesús Gay-Mimbrera, Macarena Aguilar-Luque, Isabel Viguera-Guerra, Antonio Velez García-Nieto, Beatriz Isla-Tejera & Juan Ruano. (2019) Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review. BMJ Open 9:5, pages e028303.
Crossref
Crossref
Nawaf Almutairi, Tarek M. Nour & Nasser Haji Hussain. (2019) Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study. Dermatology 235:2, pages 130-136.
Crossref
Crossref
F. Rajabi, L.A. DrakeM.M. SennaN. Rezaei. (2018) Alopecia areata: a review of disease pathogenesis. British Journal of Dermatology 179:5, pages 1033-1048.
Crossref
Crossref
F. Valenzuela, N.J. KormanR. Bissonnette, N. Bakos, T.-F. Tsai, M.K. HarperW.C. PortsH. TanA. TallmanH. ValdezA.C. Gardner. (2018) Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study. British Journal of Dermatology 179:4, pages 853-862.
Crossref
Crossref
Daniil Polykovskiy, Alexander Zhebrak, Dmitry Vetrov, Yan Ivanenkov, Vladimir Aladinskiy, Polina Mamoshina, Marine Bozdaganyan, Alexander Aliper, Alex Zhavoronkov & Artur Kadurin. (2018) Entangled Conditional Adversarial Autoencoder for de Novo Drug Discovery. Molecular Pharmaceutics 15:10, pages 4398-4405.
Crossref
Crossref
Xiang-jiang Xie, Ting-ting Di, Yan Wang, Ming-xing Wang, Yu-jiao Meng, Yan Lin, Xiao-long Xu, Ping Li & Jing-xia Zhao. (2018) Indirubin ameliorates imiquimod-induced psoriasis-like skin lesions in mice by inhibiting inflammatory responses mediated by IL-17A-producing γδ T cells. Molecular Immunology 101, pages 386-395.
Crossref
Crossref
Andrew Kim & Bruce Strober. 2018. Biologic and Systemic Agents in Dermatology. Biologic and Systemic Agents in Dermatology
187
198
.
Pawinee Rerknimitr, Atsushi Otsuka, Chisa Nakashima & Kenji Kabashima. (2017) The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflammation and Regeneration 37:1.
Crossref
Crossref
Atsushi Otsuka, Takashi Nomura, Pawinee Rerknimitr, Judith A. Seidel, Tetsuya Honda & Kenji Kabashima. (2017) The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis. Immunological Reviews 278:1, pages 246-262.
Crossref
Crossref